Neuropeptide Y Receptor-Mediated Sensitization of ATP-Stimulated Inositol Phosphate Formation

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 2, 2003, Pages 559-565

  Drakulich, D A ^a   Walls, A M ^a   Toews, M L ^a   Hexum, Terry D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; ADENOSINE TRIPHOSPHATE; CYCLIC AMP; HU 404; INOSITOL PHOSPHATE; NEUROPEPTIDE Y [13-36]; NEUROPEPTIDE Y [31 LEUCINE 34 PROLINE]; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; PERTUSSIS TOXIN;

ANIMAL CELL; ARTICLE; CELL TYPE; CHROMAFFIN CELL; CONTROLLED STUDY; EXPOSURE; HORMONE RECEPTOR INTERACTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; SECOND MESSENGER; SENSITIZATION;

ADENOSINE TRIPHOSPHATE; ANALYSIS OF VARIANCE; ANIMALS; CATTLE; CELLS, CULTURED; CHROMAFFIN CELLS; GTP-BINDING PROTEINS; INOSITOL PHOSPHATES; NEUROPEPTIDE Y; RECEPTORS, NEUROPEPTIDE Y;

EID: 0142179168     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.053082     Document Type: Article

References (36)

1. Bader R, Bettio A, Beck-Sickinger AG, and Zerbe O (2001) Structure and dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY and implications for receptor selection. J Mol Biol 305:307-329.
2. Bleakman D, Colmers WF, Fournier A, and Miller RJ (1991) Neuropeptide Y inhibits Ca2+ influx into cultured dorsal root ganglion neurones of the rat via a Y2 receptor. Br J Pharmacol 103:1781-1789.
3. Bleasdale JE, Thakur NR, Gremban RS, Bundy GL, Fitzpatrick FA, Smith RJ, and Bunting S (1990) Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther 255:756-768.
4. Boublik JH, Scott NA, Brown MR, and Rivier JE (1989) Synthesis and hypertensive activity of neuropeptide Y fragments and analogues with modified N- or C-termini or D-substitutions. J Med Chem 32:597-601.
5. Cherdchu C, Deupree JD, and Hexum TD (1989) Binding sites for 125I-neuropeptide Y (NPY) on membranes from bovine adrenal medulla. Eur J Pharmacol 173:115-119.
6. Chidiac P and Ross EM (1999) Phospholipase C-beta1 directly accelerates GTP hydrolysis by Galphaq and acceleration is inhibited by Gbeta gamma subunits. J Biol Chem 274:19639-19643.
7. Clark JT, Kalra PS, and Kalra SP (1985) Neuropeptide Y stimulates feeding but inhibits sexual behavior in rats. Endocrinology 117:2435-2442.
8. Diverse-Pierluissi M, Dunlap K, and Westhead EW (1991) Multiple actions of extra-cellular ATP on calcium currents in cultured bovine chromaffin cells. Proc Natl Acad Sci USA 88:1261-1265.
9. Erickson JC, Clegg KE, and Palmiter RD (1996) Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature (Lond) 381:415-421.
10. Gandia L, Garcia AG, and Morad M (1993) ATP modulation of calcium channels in chromaffin cells. J Physiol (Lond) 470:55-72.
11. Hinson J, Rauh C, and Coupet J (1988) Neuropeptide Y stimulates inositol phospholipid hydrolysis in rat brain miniprisms. Brain Res 446:379-382.
12. G-Acylated argininamides: highly potent selective NPY Y1 receptor antagonists with special properties. Arch Pharm Pharm Med Chem 334:17.
13. Kask A, Harro J, Von Hörsten S, Redrobe JP, Dumont Y, and Quirion R (2002) The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev 26:259-283.
14. Kataoka Y, Majane EA, and Yang HY (1985) Release of NPY-like immunoreactive material from primary cultures of chromaffin cells prepared from bovine adrenal medulla. Neuropharmacology 24:693-695.
15. Lobaugh LA and Blackshear PJ (1990) Neuropeptide Y binding and inhibition of cAMP accumulation in human neuroepithelioma cells. Am J Physiol 258:C913-C922.
16. Michel MC, Beck-Sickinger AG, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, and Westfall T (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide Y-Y and pancreatic polypeptide receptors. Pharmacol Rev 50:143-150.
17. Motulsky HJ and Michel MC (1988) Neuropeptide Y mobilizes Ca2+ and inhibits adenylate cyclase in human erythroleukemia cells. Am J Physiol 255:E880-E885.
18. Nakahata N, Martin MW, Hughes AR, Hepler JR, and Harden TK (1986) H1-histamine receptors on human astrocytoma cell. Mol Pharmacol 29:188-195.
19. Quitterer U and Lohse MJ (1999) Crosstalk between Galpha(i)- and Galpha(q)-coupled receptors is mediated by Gbetagamma exchange. Proc Natl Acad Sci USA 96:10626-10631.
20. Ralevic V and Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492.
21. Rhee SG (2001) Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 70:281-312.
22. Schmidt M, Lohmann B, Hammer K, Haupenthal S, Nehls MV, and Jakobs KH (1998) Gi- and protein kinase C-mediated heterologous potentiation of phospholipase C signaling by G protein-coupled receptors. Mol Pharmacol 53:1139-1148.
23. Schmidt M, Nehls C, Rumenapp U, and Jakobs KH (1996) m3 Muscarinic receptor-induced and Gi-mediated heterologous potentiation of phospholipase C stimulation: role of phosphoinositide synthesis. Mol Pharmacol 50:1038-1046.
24. i/o-Coupled receptors. Biochem J 328:153-158.
25. Sharma SK, Klee WA, and Nirenberg M (1975) Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 72:3092-3096.
26. Thiele TE, Marsh DJ, Ste M, Bernstein IL, and Palmiter RD (1998) Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature (Lond) 396:366-369.
27. Wahlestedt C, Ekman R, and Widerlov E (1989) Neuropeptide Y (NPY) and the central nervous system: distribution effects and possible relationship to neurological and psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 13:31-54.
28. Wahlestedt C, Regunathan S, and Reis DJ (1992) Identification of cultured cells selectively expressing Y1-, Y2-, or Y3-type receptors for neuropeptide Y/peptide YY. Life Sci 50:L7-L12.
29. Watts VJ (2002) Molecular mechanisms for heterologous sensitization of adenylate cyclase. J Pharmacol Exp Ther 302:1-7.
30. Watts VJ, Taussig R, Neve RL, and Neve KA (2001) Dopamine D2 receptor-induced heterologous sensitization of adenylyl cyclase requires Galphas: characterization of Galphas-insensitive mutants of adenylyl cyclase V. Mol Pharmacol 60:1168-1172.
31. Wilson SP and Kirshner N (1983) Preparation and maintenance of adrenal medullary chromaffin cell cultures. Methods Enzymol 103:305-312.
32. Zhang P, Zheng J, Bradley ME, and Hexum TD (2001) ATP stimulated cyclic AMP formation in bovine chromaffin cells is enhanced by neuropeptide Y. Peptides 22:439-444.
33. Zhang PJ, Zheng JL, Vorce RL, and Hexum TD (2000) Identification of an NPY-Y1 receptor subtype in bovine chromaffin cells. Regul Pept 87:9-13.
34. Zheng JL, Zhang PJ, and Hexum TD (1997a) Neuropeptide Y inhibits chromaffin cell nicotinic receptor-stimulated tyrosine hydroxylase activity through a receptor-linked G protein-mediated process. Mol Pharmacol 52:1027-1033.
35. Zheng JL, Zhang PJ, Toews M, and Hexum TD (1997b) Neuropeptide Y enhances ATP-induced formation of inositol phosphates in chromaffin cells. Biochem Biophys Res Commun 239:287-290.
36. Zhu J, Li W, Toews ML, and Hexum TD (1992) Neuropeptide Y inhibits forskolin-stimulated adenylate cyclase in bovine adrenal chromaffin cells via a pertussis toxin-sensitive process. J Pharmacol Exp Ther 263:1479-1486.